Sandhofer Str. 116
68305 Mannheim, de
+49 (8856) 60-4830
454 Life Sciences and GenomeQuest Team Up to Provide Next-Generation Sequence Search and Analysis Services
The combination of the Genome Sequencer FLX System's comprehensive sequence results and GenomeQuest's informatics tools increase both speed and convenience in converting the increasing volume of sequence data into biologically meaningful information. "With over 250 peer-reviewed publications utilizing 454 Sequencing, our customers enjoy the benefit of sophisticated bioinformatics solutions," says Chris McLeod, CEO of 454 Life Sciences, a Roche company. "Our system's long reads and analysis tools provide rapid de novo assemblies of complex genomes. Offering complementary bioinformatics tools enhances our customers' ability to quickly extract biological meaning from their experiments. GenomeQuest has proven that their annotation solutions are capable of delighting our customers."
The co-marketing agreement resulted from extensive pilot activities conducted to evaluate the scientific accuracy and scalability of GenomeQuest's algorithms and informatics platform. The goal was to assess the value that GenomeQuest could provide Genome Sequencer FLX System users. "When GenomeQuest first proposed to us the ability to computationally screen all of the sequences of an instrument run in one pass to provide annotated reads to our customers, we were hopeful, but cautious. Ultimately, they exceeded our expectations for each test case," says Edward Szekeres Jr., Manager of Production Informatics at 454 Life Sciences. "Using the annotated data in the GenomeQuest platform, our customers were able to identify novel biological findings in record time."
"As a leader in next-generation sequencing systems, we are pleased that 454 Life Sciences has validated our value proposition," says Ronald Ranauro, President and CEO of GenomeQuest. "We look forward to working closely with our colleagues at 454 Life Sciences to provide complementary informatics solutions that continue to accelerate the pace of discovery across all fields of biology."
454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative 454 Sequencing System for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of the 454 Sequencing System are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired reads. The technology of the 454 Sequencing System has enabled many peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology and many more. For additional information, please visit http://www.genome-sequencing.com
About GenomeQuest, Inc.
GenomeQuest, Inc. is the leading sequence informatics company providing applications and services to manage and mine the world's sequence data. The company's flagship product, GenomeQuest, is a web-based sequence information platform that enables users to exploit genomic information resources including next-generation sequencing tools and worldwide biological sequence reference databases. GenomeQuest's customers leverage high-speed algorithms and sophisticated analysis and reporting to transform data into functional knowledge, on-demand. GenomeQuest delivers genomic data access, management, and utility to over 150 leading life science companies worldwide. For more information visit www.genomequest.com
454, 454 SEQUENCING, 454 LIFE SCIENCES, GENOME SEQUENCER, GS FLX TITANIUM are trademarks of Roche.
GenomeQuest is a trademark of GenomeQuest, Inc.
Other brands and product names are trademarks of their respective holders
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.